Related Experiment Video
Updated: Apr 25, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
Emerging drugs for levodopa-induced dyskinesia
Amaal Al Dakheel1, Isabelle Beaulieu-Boire, Susan H Fox
1Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network , Toronto, ON , Canada.
Expert Opinion on Emerging Drugs
|August 23, 2014
Summary
Levodopa is key for Parkinson's disease, but causes dyskinesia. New research focuses on continuous stimulation or non-dopaminergic targets to manage levodopa-induced dyskinesia (LID) effectively.
Area of Science:
- Neuroscience
- Pharmacology
- Movement Disorders
Background:
- Levodopa is the primary symptomatic treatment for Parkinson's disease.
- Prolonged levodopa use frequently results in debilitating motor complications, specifically levodopa-induced dyskinesia (LID).
- Current pharmacological options for managing established LID are limited and often cause side effects.
Purpose of the Study:
- To review novel therapeutic strategies for managing levodopa-induced dyskinesia (LID) in Parkinson's disease.
- To explore treatments aimed at preventing or delaying the onset of LID.
- To identify agents that enable effective levodopa use without inducing LID.
Main Methods:
- Review of ongoing and recently published randomized controlled trials (ClinicalTrials.gov).
- Analysis of research focusing on continuous dopaminergic receptor stimulation.
- Investigation of levodopa-sparing strategies and non-dopaminergic targets.
Main Results:
- LID pathophysiology involves basal ganglia circuitry modifications and altered neurotransmitter signaling.
- Novel treatments target continuous dopaminergic stimulation or non-dopaminergic pathways (glutamatergic, serotonergic, adenosine, adrenergic, cholinergic).
- Research is exploring agents to prevent LID and improve levodopa efficacy.
Conclusions:
- Future therapeutic success for LID hinges on advancements in translational research.
- Developing agents for continuous dopaminergic stimulation is a key research goal.
- Targeting non-dopaminergic systems offers promising avenues for LID management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.9K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.1K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
1.2K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.2K